ea0065p235 | Metabolism and Obesity | SFEBES2019
Lucey Maria
, Pickford Phil
, Ma Yue
, Shchepinova Maria
, Tate Ed
, McGinty James
, French Paul
, Davies Samuel
, Xavier Gabriela Da Silva
, Stolarczyk Emilie
, Minnion James
, Rutter Guy
, Bloom Steve
, Tomas Alejandra
, Jones Ben
Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective treatments for type 2 diabetes and obesity. We recently described ‘biased’ peptide GLP-1R agonists modelled on exendin-4 which uncouple the pronounced endocytosis that usually accompanies GLP-1R activation, leading to prolongation of intracellular signalling responses. Here, we show that the metabolic consequences of biased GLP-1R activation in vivo are dominated by improvements in blood glucos...